Teva and Natco Launch Additional Strengths for the Generic Version of Revlimid in the US
17 March 2023 - - Israel-based Teva Pharmaceutical Industries Ltd's (NYSE: TEVA) (TASE: TEVA) Teva Pharmaceuticals US affiliate and NATCO Pharma Ltd. (NSE: NATCOPHARM) (BSE: 524816) has launched additional strengths for the generic version of Revlimid (lenalidomide capsules), in 2.5 mg, and 20 mg strengths, in the United States, the company said.

The companies have launched four other strengths of the product in March 2022 in the US market. With today's launch the companies made available all the strengths of lenalidomide in the US market.

Teva's lenalidomide capsules are a prescription medicine used in adults for the treatment of multiple myeloma in combination with the medicine dexamethasone, certain myelodysplastic syndromes, and mantle cell lymphoma following specific prior treatment.

With nearly 500 generic medicines available, Teva has the largest portfolio of FDA-approved generic products on the market, and holds the leading position in first-to-file opportunities, with approximately 100 pending first-to-files in the US.

Currently, 1 in 12 generic prescriptions dispensed in the US is filled with a Teva generic product.

Revlimid had annual sales of USD 2.9bn as of January, 2023, according to IQVIA data.

What are lenalidomide capsules?

Lenalidomide capsules are a prescription medicine, used to treat adults with:

multiple myeloma
in combination with the medicine dexamethasone
a condition called myelodysplastic syndromes. Lenalidomide capsules are for the type of MDS with a chromosome problem where part of chromosome 5 is missing.

This type of MDS is known as deletion 5q MDS. People with this type of MDS may have low red blood cell counts that require treatment with blood transfusions.

mantle cell lymphoma when the disease comes back or becomes worse after treatment with 2 prior medicines, one of which included bortezomib. MCL is a cancer of a type of white blood cell called lymphocytes that are in the lymph nodes.

Lenalidomide capsules should not be used to treat people who have chronic lymphocytic leukemia unless they are participants in a controlled clinical trial.

It is not known if lenalidomide capsules are safe and effective in children.